About NervGen
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company’s initial focus is on spinal cord injury, Alzheimer’s and multiple sclerosis. Our lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. Studies in patients are planned to initiate in 2023.